Alzheimer Europe

Today, the European Medicines Agency’s Committee for Medicinal Products for Human use issued a negative opinion on the marketing authorisation application of Eisai EMEA for lecanemab, for the treatment of early #Alzheimer’s disease. Alzheimer Europe regrets the negative European Medicines Agency opinion, which may deprive Europeans with Alzheimer’s disease from a medicine that is available in the US and other global regions. We fear that this opinion takes away choice from individuals with early Alzheimer’s disease, and advocate for individuals with Alzheimer’s disease and their families to be included in assessing the risks and benefits of new medicines. Alzheimer Europe reiterates its call for continued research into treatment options for Alzheimer’s disease and other dementias, including symptomatic treatments as well as therapies for people in more advanced stages. Read our full statement: https://lnkd.in/eMqMMrc8

Following the negative European Medicines Agency opinion on their Marketing Authorisation Application for #lecanemab, Eisai & Biogen announce that they will seek re-examination by the Committee for Medicinal Products for Human Use (CHMP) #AEScienceWatch Read more ➡ https://lnkd.in/e7Enmp4V

European Commission publishes guideline on regulation on air passengers rights for persons with disabilities https://lnkd.in/em7jgGXn

New WHO report highlights strategies for age-friendly cities in post-pandemic era https://lnkd.in/eJzPENe4

"Quality of life and equal opportunities have to be guaranteed for people living with dementia everywhere in Europe. Support Alzheimer Europe’s call to action for European leaders to make dementia a priority." ⤵️ https://lnkd.in/e8zQssrC Chris Ellermaa #DementiaNeedsEU

Congratulations to our partners at the European Platform for Neurodegenerative Diseases (EPND) on the launch of their Call for Expressions of Interest! #neurodegeneration researchers are invited to submit proposals to leverage #biosamples and datasets catalogued on the Platform. The Call is open to researchers at all career stages, working in academia or in industry, and successful applicants will benefit from a wide range of resources and services provided by the project. Learn more and apply by 15 September!   Innovative Health Initiative (IHI) EFPIA - European Federation of Pharmaceutical Industries and Associations https://lnkd.in/ey9TMYPb

Earlier this month, TauRx Pharmaceuticals Ltd. announced the submission of a UK marketing authorisation application for their oral drug, HMTM. HMTM is being assessed under the MHRA’s Innovative Licencing and Access Pathway #AEScienceWatch https://lnkd.in/eEJ2shp3

A recent systematic review published in the Lancet Public Health examined trends over time in the incidence and prevalence of dementia, as well as its risk factors. Find out more! https://lnkd.in/eTzD8saG

Recent study from Karolinska Institutet found that stress may weaken the benefits of cognitive reserve on cognitive functioning. The study found that higher cognitive reserve scores were associated with better cognition, but this link was attenuated when accounting for physiological stress. #Alzheimer’s disease #AEScienceWatch https://lnkd.in/ebFgBiYJ

Today is #WorldBrainDay! #DidYouKnow that an estimated 40% of #dementias could potentially be prevented by addressing modifiable risk factors? On World Brain Day 2024, we are shining a spotlight on #BrainHealth and dementia prevention. Building on innovations including the FINGER model for dementia prevention, AD-RIDDLE is creating a modular toolbox platform to deliver personalised support at all stages of the clinical pathway. Together with out 24 partners across Europe and beyond, we will advance the detection, prevention and treatment of #Alzheimer's disease and other dementias 🌟 Learn more ▶ https://lnkd.in/eihaGs8j Innovative Health Initiative (IHI) Region Stockholm Karolinska Institutet Gates Ventures FINGERS Brain Health Institute University of Gothenburg Lund University UEF Brain Research Unit | UEF Aivotutkimusyksikkö Amsterdam UMC Maastricht University Fundación Pasqual Maragall University of Leicester Imperial College London SYNAPSE Research Management Partners Alzheimer Europe Alzheimer's Disease International Università degli Studi di Perugia NICE - National Institute for Health and Care Excellence Davos Alzheimer's Collaborative Combinostics Fujirebio Europe Cambridge Cognition Sanofi C2N Diagnostics neotiv